FIMBRION THERAPEUTICS INC
Saint Louis, MO · Biotech · Private
Small molecule FimH antagonists and FimH-ARM (antibody-recruiting molecule) therapeutics that inhibit bacterial adhesion to treat urinary tract infections
fimbrion.com →- Grants
- $7.9M
- 16 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 16
- 6 granted · 10 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Anti-virulence FimH inhibitors for the treatment and prevention of UTIs | $269,019 | |
| Federal grant | Department of Health and Human Services · Phase II · Anti-Virulence FimH Inhibitors for the Treatment and Prevention of UTIs | $901,235 | |
| Federal grant | Department of Health and Human Services · Phase II · Anti-Virulence FimH Inhibitors for the Treatment and Prevention of UTIs | $724,797 | |
| Federal grant | Department of Health and Human Services · Phase I · Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis | $293,050 | |
| Federal grant | Department of Health and Human Services · Phase II · Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis | $997,875 | |
| Federal grant | Department of Health and Human Services · Phase I · FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Thiazolino-Pyridone Compounds as Novel Drugs for Tuberculosis | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis | $994,977 | |
| Federal grant | Department of Health and Human Services · Phase I · FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Thiazolino-Pyridone Compounds as Novel Drugs for Tuberculosis | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Heterocyclic Inhibitors of QcrB as Novel Drugs for Infections Caused by Nontuberculous Mycobacteria | $300,001 | |
| Federal grant | Department of Health and Human Services · Phase I · Small Molecule Glycoside Inhibitors of LecB for the Treatment of Pseudomonas Infections | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Thiazolino-Pyridone Compounds as Novel Antimycobacterial Drugs for Tuberculosis | $300,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2898 | Beeline Medicines | — | — |
| 2899 | GENERATION BIOTECH, LLC | — | — |
| 2900 | ARTERY THERAPEUTICS INC | — | — |
| 2901 | FIMBRION THERAPEUTICS INC | — | — |
| 2902 | 712 North Inc. | — | — |
| 2903 | SIMMBION LLC | — | — |
| 2904 | Dyno Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- C-mannoside Compounds Useful For The Treatment Of Urinary Tract Infectionsapplication
- Substituted Biphenyl Or Phenylheteroaryl-mannosides As Antagonists Of Fimhapplication
- C-mannoside Compounds Useful For The Treatment Of Urinary Tract Infectionsgranted
- Substituted Biphenyl Or Phenylheteroaryl-mannosides As Antagonists Of Fimhgranted
- Novel Compoundsgranted
- Mannose-derived Antagonists Of Fimh Useful For Treating Diseaseapplication
- C-mannoside Compounds Useful For The Treatment Of Urinary Tract Infectionsgranted
- Mannose-derived Antagonists Of Fimh Useful For Treating Diseaseapplication
- C-mannoside Compounds Useful For The Treatment Of Urinary Tract Infectionsgranted
- Mannose-derived Antagonists Of Fimh Useful For Treating Diseaseapplication
- Mannose-derived Antagonists Of Fimh Useful For Treating Diseasegranted
- C-glycoside Compounds Useful For Treating Diseaseapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.